Deferoxamine pharmacokinetics

doi:10.1016/S0037-1963(01)90061-7

Seminars in Hematology

Volume 38, Supplement 1, January 2001, Pages 63-68

https://doi.org/10.1016/S0037-1963(01)90061-7 Get rights and content

Abstract

Despite the clinical use of deferoxamine for more than a quarter of a century, pharmacokinetic studies are few and have not been performed explicitly in patients with sickle cell disorders. Early studies with intravenous administration to healthy volunteers and patients with transfusional overload showed that although peak concentrations of deferoxamine were similar in both groups, concentrations of ferrioxamine were higher in the latter. In iron-overloaded patients with hereditary hemochromatosis, an intramuscular 10 mg/kg bolus of deferoxamine gave maximal plasma ferrioxamine concentrations exceeding those of deferoxamine, whereas in normal controls the reverse was the case. In more recent studies with homozygous β-thalassemia, using continuous intravenous deferoxamine infusion at 50 mg/kg/d, and initial elimination half-life of 0.28/h and steady-state concentration of 7 μmol/L were observed. In these studies, steady-state plasma levels of the predominant deferoxamine metabolite B were usually lower than those of unmetabolized deferoxamine. In a further intravenous infusion study, the proportion of plasma metabolites was higher in those thalassaemia patients with low serum ferritin levels relative to their current mean daily deferoxamine dose, suggesting that high metabolite levels may predict excessive desferrioxamine dosing. This hypothesis is supported by subcutaneous studies in which low doses of slow-release depot deferoxamine resulted in significantly lower proportions of plasma metabolites than with conventional 8-hour infusions at 40 mg/kg. Because serum ferritin is particularly unreliable as a marker of iron overload in sickle cell disorders, measurement of metabolites or the relative proportions of deferoxamine and ferrioxamine may help identify patients at risk of excessive dosing. Because iron overload is likely to become an increasing issue in patients with sickle cell disorders, studies of the pharmacokinetics and metabolism of deferoxamine in this patient group are needed.

References (15)

S Singh et al.
Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection
Anal Biochem
(1992)
P Allain et al.
Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis
Br J Clin Pharmacol
(1987)
GB Arden et al.
Ocular changes in patients undergoing long-term desferrioxamine treatment
Br J Opthalmol
(1984)
B Gee et al.
Unbound iron binding capacity: Correlation with non-transferrin bound plasma iron and deferoxamine levels
P Lee et al.
Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemia patients
Drugs Metab Disp
(1993)
MJ Pippard et al.
Intensive iron-chelation with desferrioxamine in iron-loading anaemias
Clin Sci Mol Med
(1978)
JB Porter et al.
Subcutaneous depot desferrioxamine (CGH 749B): Relationship of pharmacokinetics to efficacy and drug metabolism
Blood
(1997)

There are more references available in the full text version of this article.

Cited by (60)

Vascularized 3D printed scaffolds for promoting bone regeneration
2019, Biomaterials
3D printed scaffolds hold promising perspective for bone tissue regeneration. Inspired by process of bone development stage, 3D printed scaffolds with rapid internal vascularization ability and robust osteoinduction bioactivity will be an ideal bone substitute for clinical use. Here, we fabricated a 3D printed biodegradable scaffold that can control release deferoxamine, via surface aminolysis and layer-by-layer assembly technique, which is essential for angiogenesis and osteogenesis and match to bone development and reconstruction. Our in vitro studies show that the scaffold significantly accelerates the vascular pattern formation of human umbilical endothelial cells, boosts the mineralized matrix production, and the expression of osteogenesis-related genes during osteogenic differentiation of mesenchymal stem cells. In vivo results show that deferoxamine promotes the vascular ingrowth and enhances the bone regeneration at the defect site in a rat large bone defect model. Moreover, this 3D-printed scaffold has excellent biocompatibility that is suitable for mesenchymal stem cells grow and differentiate and possess the appropriate mechanical property that is similar to natural cancellous bone. In summary, this 3D-printed scaffold holds huge potential for clinical translation in the treatment of segmental bone defect, due to its flexibility, economical friendly and practicality.
Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response
2019, Biomaterials
Citation Excerpt :
Although DFX most likely sequestered excess available free iron and did upregulate the antioxidant activity at the earliest time-point, it was not able to decrease the overall activation of ROS producing species by 7-day. This may have been due to an abundance of reactive oxygen and nitrogen species at later time-points as well as unavailability of DFX due to its short half-life (∼6-h) [76], which may warrant a larger, more frequent administration of the drug. Significant evidence demonstrates the profound activation and recruitment of immune cells to the injury site following intracortical electrode at acute [147] and chronic time-points [117,148].
The use of intracortical microelectrode arrays has gained significant attention in being able to help restore function in paralysis patients and study the brain in various neurological disorders. Electrode implantation in the cortex causes vasculature or blood-brain barrier (BBB) disruption and thus elicits a foreign body response (FBR) that results in chronic inflammation and may lead to poor electrode performance. In this study, a comprehensive insight into the acute molecular mechanisms occurring at the Utah electrode array-tissue interface is provided to understand the oxidative stress, neuroinflammation, and neurovascular unit (astrocytes, pericytes, and endothelial cells) disruption that occurs following microelectrode implantation. Quantitative real time polymerase chain reaction (qRT-PCR) was used to quantify the gene expression at acute time-points of 48-hr, 72-hr, and 7-days for factors mediating oxidative stress, inflammation, and BBB disruption in rats implanted with a non-functional 4 × 4 Utah array in the somatosensory cortex. During vascular disruption, free iron released into the brain parenchyma can exacerbate the FBR, leading to oxidative stress and thus further contributing to BBB degradation. To reduce the free iron released into the brain tissue, the effects of an iron chelator, deferoxamine mesylate (DFX), was also evaluated.
A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
2018, Blood Reviews
Citation Excerpt :
Evidence suggests that the short-term clinical effectiveness of all three iron chelators is similar [73], although efficacy in different organs may vary [74,75]. Deferoxamine, the first commercially available iron chelator, is administered by parenteral infusion for 8–12 hours, 5–7 nights per week [67,71,76]. The benefits of deferoxamine are well documented [63,64], but the demanding treatment regimen can lead to poor adherence [1,77].
Beta-thalassaemia causes defective haemoglobin synthesis leading to ineffective erythropoiesis, chronic haemolytic anaemia, and subsequent clinical complications. Blood transfusion and iron chelation allow long-term disease control, and haematopoietic stem cell transplantation offers a potential cure for some patients. Nonetheless, there are still many challenges in the management of beta-thalassaemia. The main treatment option for most patients is supportive care; furthermore, the long-term efficacy and safety of current therapeutic strategies are limited and adherence is suboptimal. An increasing understanding of the underlying molecular and cellular disease mechanisms plus an awareness of limitations of current management strategies are driving research into novel therapeutic options. Here we provide an overview of the current pathophysiology, clinical manifestations, and global burden of beta-thalassaemia. We reflect on what has been achieved to date, describe the challenges associated with currently available therapy, and discuss how these issues might be addressed by novel therapeutic approaches in development.
Contemporary approaches to treatment of beta-thalassemia intermedia
2012, Blood Reviews
Beta-thalassemia intermedia (TI) is associated with a variety of serious clinical complications that require proactive and comprehensive management. These include skeletal deformities and osteopenia, compensatory extramedullary hematopoiesis and tumor formation, progressive splenomegaly, a hypercoagulable state resulting in thromboembolic events and pulmonary hypertension, and increased gastrointestinal iron absorption that often results in nontransfusional iron overload and liver damage. Although TI is generally considered a non-transfusion-dependent thalassemia, transfusion therapy may be an important part of the comprehensive management of this disease. This review describes the current state of the art for medical management of TI, with particular focus on the roles of splenectomy, transfusion, and iron chelation therapy.
Design and synthesis of fluorine-substituted 3-hydroxypyridin-4-ones
2010, Tetrahedron Letters
Circulating Iron in Patients with Sickle Cell Disease Mediates the Release of Neutrophil Extracellular Traps
2023, Transfusion Medicine and Hemotherapy

View all citing articles on Scopus

View full text

Deferoxamine pharmacokinetics

Abstract

Anal Biochem

Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis

Br J Clin Pharmacol

Ocular changes in patients undergoing long-term desferrioxamine treatment

Br J Opthalmol

Unbound iron binding capacity: Correlation with non-transferrin bound plasma iron and deferoxamine levels

Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemia patients

Drugs Metab Disp

Intensive iron-chelation with desferrioxamine in iron-loading anaemias

Clin Sci Mol Med

Subcutaneous depot desferrioxamine (CGH 749B): Relationship of pharmacokinetics to efficacy and drug metabolism

Blood